MAPT and Alzheimer disease: Based on this previous literature, we designed a multi-site biomarker study including three cohorts to test the hypothesis that the presence of astrocyte reactivity biomarker abnormality is a key element determining the association of Aβ with early tau phosphorylation and aggregation biomarkers in preclinical AD.